Implantable Hemodynamic Monitoring for Heart Failure Patients

Rates of heart failure hospitalization remain unacceptably high. Such hospitalizations are associated with substantial patient, caregiver, and economic costs. Randomized controlled trials of noninvasive telemedical systems have failed to demonstrate reduced rates of hospitalization. The failure of t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2017-07, Vol.70 (3), p.389-398
Hauptverfasser: Abraham, William T., Perl, Leor
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 398
container_issue 3
container_start_page 389
container_title Journal of the American College of Cardiology
container_volume 70
creator Abraham, William T.
Perl, Leor
description Rates of heart failure hospitalization remain unacceptably high. Such hospitalizations are associated with substantial patient, caregiver, and economic costs. Randomized controlled trials of noninvasive telemedical systems have failed to demonstrate reduced rates of hospitalization. The failure of these technologies may be due to the limitations of the signals measured. Intracardiac and pulmonary artery pressure–guided management has become a focus of hospitalization reduction in heart failure. Early studies using implantable hemodynamic monitors demonstrated the potential of pressure-based heart failure management, whereas subsequent studies confirmed the clinical utility of this approach. One large pivotal trial proved the safety and efficacy of pulmonary artery pressure–guided heart failure management, showing a marked reduction in heart failure hospitalizations in patients randomized to active pressure-guided management. “Next-generation” implantable hemodynamic monitors are in development, and novel approaches for the use of this data promise to expand the use of pressure-guided heart failure management. [Display omitted]
doi_str_mv 10.1016/j.jacc.2017.05.052
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1920194668</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0735109717375940</els_id><sourcerecordid>1919455947</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-2c6c0014830f6680a89d532119b0b6f6e0d81a7ccb06cba7aad62ec003117cd13</originalsourceid><addsrcrecordid>eNp9kM9KxDAQh4Mo7vrnBTxIwYuXrpN2k7QggiyuK6zoQc8hTaeS0jZr0gr7Nj6LT2aWXT14EAbm8v1-M3yEnFGYUKD8qp7USutJAlRMgIVJ9siYMpbFKcvFPhmDSFlMIRcjcuR9DQA8o_khGSWZAJYmdExuHtpVo7peFQ1GC2xtue5Ua3T0aDvTW2e6t6iy7utzgcr10VyZZnAYPaveYNf7E3JQqcbj6W4fk9f53ctsES-f7h9mt8tYp9m0jxPNNQCdZilUnGegsrzc3Kd5AQWvOEKZUSW0LoDrQgmlSp5giKSUCl3S9JhcbntXzr4P6HvZGq-xCa-jHbykebCQT0N3QC_-oLUdXBe-C1RgGMunIlDJltLOeu-wkitnWuXWkoLc2JW13NiVG7sSWJgkhM531UPRYvkb-dEZgOstgMHFh0EnvQ6eNJbGoe5lac1__d9YlIpE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1919455947</pqid></control><display><type>article</type><title>Implantable Hemodynamic Monitoring for Heart Failure Patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Abraham, William T. ; Perl, Leor</creator><creatorcontrib>Abraham, William T. ; Perl, Leor</creatorcontrib><description>Rates of heart failure hospitalization remain unacceptably high. Such hospitalizations are associated with substantial patient, caregiver, and economic costs. Randomized controlled trials of noninvasive telemedical systems have failed to demonstrate reduced rates of hospitalization. The failure of these technologies may be due to the limitations of the signals measured. Intracardiac and pulmonary artery pressure–guided management has become a focus of hospitalization reduction in heart failure. Early studies using implantable hemodynamic monitors demonstrated the potential of pressure-based heart failure management, whereas subsequent studies confirmed the clinical utility of this approach. One large pivotal trial proved the safety and efficacy of pulmonary artery pressure–guided heart failure management, showing a marked reduction in heart failure hospitalizations in patients randomized to active pressure-guided management. “Next-generation” implantable hemodynamic monitors are in development, and novel approaches for the use of this data promise to expand the use of pressure-guided heart failure management. [Display omitted]</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/j.jacc.2017.05.052</identifier><identifier>PMID: 28705321</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Beta blockers ; Cardiology ; Clinical outcomes ; Clinical trials ; Control systems ; Cost engineering ; disease management ; Economic impact ; Equipment Design ; Heart diseases ; Heart failure ; Heart Failure - diagnosis ; Heart Failure - physiopathology ; Heart rate ; Hemodynamics ; Hospitalization ; Hospitals ; Humans ; Monitoring, Physiologic - instrumentation ; Monitors ; Morbidity ; Mortality ; patient readmission ; Patients ; Physiology ; Pressure ; Pulmonary arteries ; Pulmonary artery ; pulmonary artery pressure ; Pulmonary hypertension ; Quality of life ; Remote Sensing Technology - instrumentation ; Telemedicine ; Veins &amp; arteries</subject><ispartof>Journal of the American College of Cardiology, 2017-07, Vol.70 (3), p.389-398</ispartof><rights>2017 American College of Cardiology Foundation</rights><rights>Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Jul 18, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-2c6c0014830f6680a89d532119b0b6f6e0d81a7ccb06cba7aad62ec003117cd13</citedby><cites>FETCH-LOGICAL-c384t-2c6c0014830f6680a89d532119b0b6f6e0d81a7ccb06cba7aad62ec003117cd13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0735109717375940$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28705321$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abraham, William T.</creatorcontrib><creatorcontrib>Perl, Leor</creatorcontrib><title>Implantable Hemodynamic Monitoring for Heart Failure Patients</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>Rates of heart failure hospitalization remain unacceptably high. Such hospitalizations are associated with substantial patient, caregiver, and economic costs. Randomized controlled trials of noninvasive telemedical systems have failed to demonstrate reduced rates of hospitalization. The failure of these technologies may be due to the limitations of the signals measured. Intracardiac and pulmonary artery pressure–guided management has become a focus of hospitalization reduction in heart failure. Early studies using implantable hemodynamic monitors demonstrated the potential of pressure-based heart failure management, whereas subsequent studies confirmed the clinical utility of this approach. One large pivotal trial proved the safety and efficacy of pulmonary artery pressure–guided heart failure management, showing a marked reduction in heart failure hospitalizations in patients randomized to active pressure-guided management. “Next-generation” implantable hemodynamic monitors are in development, and novel approaches for the use of this data promise to expand the use of pressure-guided heart failure management. [Display omitted]</description><subject>Beta blockers</subject><subject>Cardiology</subject><subject>Clinical outcomes</subject><subject>Clinical trials</subject><subject>Control systems</subject><subject>Cost engineering</subject><subject>disease management</subject><subject>Economic impact</subject><subject>Equipment Design</subject><subject>Heart diseases</subject><subject>Heart failure</subject><subject>Heart Failure - diagnosis</subject><subject>Heart Failure - physiopathology</subject><subject>Heart rate</subject><subject>Hemodynamics</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Monitoring, Physiologic - instrumentation</subject><subject>Monitors</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>patient readmission</subject><subject>Patients</subject><subject>Physiology</subject><subject>Pressure</subject><subject>Pulmonary arteries</subject><subject>Pulmonary artery</subject><subject>pulmonary artery pressure</subject><subject>Pulmonary hypertension</subject><subject>Quality of life</subject><subject>Remote Sensing Technology - instrumentation</subject><subject>Telemedicine</subject><subject>Veins &amp; arteries</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM9KxDAQh4Mo7vrnBTxIwYuXrpN2k7QggiyuK6zoQc8hTaeS0jZr0gr7Nj6LT2aWXT14EAbm8v1-M3yEnFGYUKD8qp7USutJAlRMgIVJ9siYMpbFKcvFPhmDSFlMIRcjcuR9DQA8o_khGSWZAJYmdExuHtpVo7peFQ1GC2xtue5Ua3T0aDvTW2e6t6iy7utzgcr10VyZZnAYPaveYNf7E3JQqcbj6W4fk9f53ctsES-f7h9mt8tYp9m0jxPNNQCdZilUnGegsrzc3Kd5AQWvOEKZUSW0LoDrQgmlSp5giKSUCl3S9JhcbntXzr4P6HvZGq-xCa-jHbykebCQT0N3QC_-oLUdXBe-C1RgGMunIlDJltLOeu-wkitnWuXWkoLc2JW13NiVG7sSWJgkhM531UPRYvkb-dEZgOstgMHFh0EnvQ6eNJbGoe5lac1__d9YlIpE</recordid><startdate>20170718</startdate><enddate>20170718</enddate><creator>Abraham, William T.</creator><creator>Perl, Leor</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20170718</creationdate><title>Implantable Hemodynamic Monitoring for Heart Failure Patients</title><author>Abraham, William T. ; Perl, Leor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-2c6c0014830f6680a89d532119b0b6f6e0d81a7ccb06cba7aad62ec003117cd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Beta blockers</topic><topic>Cardiology</topic><topic>Clinical outcomes</topic><topic>Clinical trials</topic><topic>Control systems</topic><topic>Cost engineering</topic><topic>disease management</topic><topic>Economic impact</topic><topic>Equipment Design</topic><topic>Heart diseases</topic><topic>Heart failure</topic><topic>Heart Failure - diagnosis</topic><topic>Heart Failure - physiopathology</topic><topic>Heart rate</topic><topic>Hemodynamics</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Monitoring, Physiologic - instrumentation</topic><topic>Monitors</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>patient readmission</topic><topic>Patients</topic><topic>Physiology</topic><topic>Pressure</topic><topic>Pulmonary arteries</topic><topic>Pulmonary artery</topic><topic>pulmonary artery pressure</topic><topic>Pulmonary hypertension</topic><topic>Quality of life</topic><topic>Remote Sensing Technology - instrumentation</topic><topic>Telemedicine</topic><topic>Veins &amp; arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abraham, William T.</creatorcontrib><creatorcontrib>Perl, Leor</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abraham, William T.</au><au>Perl, Leor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Implantable Hemodynamic Monitoring for Heart Failure Patients</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>2017-07-18</date><risdate>2017</risdate><volume>70</volume><issue>3</issue><spage>389</spage><epage>398</epage><pages>389-398</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><abstract>Rates of heart failure hospitalization remain unacceptably high. Such hospitalizations are associated with substantial patient, caregiver, and economic costs. Randomized controlled trials of noninvasive telemedical systems have failed to demonstrate reduced rates of hospitalization. The failure of these technologies may be due to the limitations of the signals measured. Intracardiac and pulmonary artery pressure–guided management has become a focus of hospitalization reduction in heart failure. Early studies using implantable hemodynamic monitors demonstrated the potential of pressure-based heart failure management, whereas subsequent studies confirmed the clinical utility of this approach. One large pivotal trial proved the safety and efficacy of pulmonary artery pressure–guided heart failure management, showing a marked reduction in heart failure hospitalizations in patients randomized to active pressure-guided management. “Next-generation” implantable hemodynamic monitors are in development, and novel approaches for the use of this data promise to expand the use of pressure-guided heart failure management. [Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28705321</pmid><doi>10.1016/j.jacc.2017.05.052</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0735-1097
ispartof Journal of the American College of Cardiology, 2017-07, Vol.70 (3), p.389-398
issn 0735-1097
1558-3597
language eng
recordid cdi_proquest_miscellaneous_1920194668
source MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Beta blockers
Cardiology
Clinical outcomes
Clinical trials
Control systems
Cost engineering
disease management
Economic impact
Equipment Design
Heart diseases
Heart failure
Heart Failure - diagnosis
Heart Failure - physiopathology
Heart rate
Hemodynamics
Hospitalization
Hospitals
Humans
Monitoring, Physiologic - instrumentation
Monitors
Morbidity
Mortality
patient readmission
Patients
Physiology
Pressure
Pulmonary arteries
Pulmonary artery
pulmonary artery pressure
Pulmonary hypertension
Quality of life
Remote Sensing Technology - instrumentation
Telemedicine
Veins & arteries
title Implantable Hemodynamic Monitoring for Heart Failure Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T01%3A00%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Implantable%20Hemodynamic%20Monitoring%20for%C2%A0Heart%20Failure%20Patients&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Abraham,%20William%20T.&rft.date=2017-07-18&rft.volume=70&rft.issue=3&rft.spage=389&rft.epage=398&rft.pages=389-398&rft.issn=0735-1097&rft.eissn=1558-3597&rft_id=info:doi/10.1016/j.jacc.2017.05.052&rft_dat=%3Cproquest_cross%3E1919455947%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1919455947&rft_id=info:pmid/28705321&rft_els_id=S0735109717375940&rfr_iscdi=true